A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients

Background: Constructed an immune-prognosis index (IPI) and divided lung adenocarcinoma (LUAD) patients into different subgroups according to IPI score, describe the molecular and immune characteristics of patients between different IPI subgroups, and explore their response to immune checkpoint bloc...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Yuquan, Pei, Yun, Xia, Liang, Ma, Lin, Deng, Senyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124834/
https://www.ncbi.nlm.nih.gov/pubmed/35614936
http://dx.doi.org/10.3389/fphar.2022.818170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124834/
https://www.ncbi.nlm.nih.gov/pubmed/35614936
http://dx.doi.org/10.3389/fphar.2022.818170

Ejemplares similares